LUNG CANCER

Experts in lung oncology review 3 clinical cases and discuss individualized treatment approaches for each patient.

Vivek Subbiah, MD, discusses the implications of the phase 1/2 LIBRETTO-001 study, which evaluated selpercatinib as treatment of patients with RET fusion-positive non–small cell lung cancer.

The FDA has granted approval to a generic form of the chemotherapy agent pemetrexed, which is indicated for intravenous administration in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer that have not progressed following 4 cycles of first-line platinum-based chemotherapy.

The FDA accepted a New Drug Application for tepotinib and granted it priority review for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test.

A quality improvement tool called “Improving Care Coordination: A Model for Lung Cancer” released by the Association of Community Cancer Centers is a model framework to be used by cancer care providers to improve care coordination for patients with lung cancer who are covered by Medicaid.

Medstar Georgetown University Hospital’s Dr Stephen Liu shares impressions on the way a 57-year-old man with ALK-positive metastatic non–small cell lung cancer was managed, highlighting the rationale for using a second-generation ALK inhibitor as treatment.

The application of liquid biopsies is becoming more common in the field of non–small cell lung cancer as the utility of liquid biopsies in the detection of key biomarkers continues to be confirmed through clinical trials.

Objective response rates for repotrectinib in patients with ROS1-positive non–small cell lung cancer and NTRK fusion-positive advanced solid tumors are encouraging, according to interim data from the phase 2 TRIDENT-1 clinical trial.

The FDA has accepted a Biologics License Application for a new 4-week fixed-dose regimen containing durvalumab and granted it Priority Review for the approved indications of non–small cell lung cancer, as well as bladder cancer.

The FDA granted Priority Review to the New Drug Application for trilaciclib for the treatment of patients with small cell lung cancer who are receiving chemotherapy.

Nivolumab in combination with ipilimumab significantly improved overall survival (OS) in treatment-naïve patients with unresectable malignant pleural mesothelioma (MPM) who were treated in the phase 3 CheckMate 743 clinical trial.

The combination of CS1001 and chemotherapy led to an improvement in progression-free survival among patients with stage IV squamous and non-squamous non–small cell lung cancer, according to data from the phase 3 CS1001-302 clinical trial assessed by an Independent Data Monitoring Committee, achieving the study’s primary end point.

Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib for lung cancer with ROS1 fusions and how to treat them.

In response to the COVID-19 pandemic, the European Society of Medical Oncology has published recommendations for the management of patients with lung cancer to maintain high-quality standards of treatment.

The FDA granted Breakthrough Therapy designation to osimertinib as adjuvant treatment of patients with stage IB-IIIA EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

Leora Horn, MD, MSc, discusses the real-world data outcomes compared with clinical trial data of mobocertinib from a retrospective study in patients with refractory non–small cell lung cancer with EGFR exon 20 insertions.

Jared Weiss, MD, discusses the pooled analysis of 3 phase 2 trials looking at trilaciclib in patients with extensive-stage small cell lung cancer.